Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M670Revenue $M318Net Margin (%)11.0Z-Score3.8
Enterprise Value $M704EPS $0.8Operating Margin %13.2F-Score5
P/E(ttm))17.6Cash Flow Per Share $1.3Pre-tax Margin (%)11.1Higher ROA y-yN
Price/Book2.910-y EBITDA Growth Rate %3.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales1.95-y EBITDA Growth Rate %10.8Current Ratio2.2Lower Leverage y-yY
Price/Cash Flow8.9y-y EBITDA Growth Rate %9.3ROA % (ttm)8.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)17.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M31.0ROI % (ttm)25.6Gross Margin Increase y-yY

Gurus Latest Trades with CBM

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CBMJoel Greenblatt 2013-03-31 Sold Out -0.09%$11.27 - $12.79
($11.93)
$ 21.6281%Sold Out0
CBMJoel Greenblatt 2012-12-31 Buy 0.09%$9.34 - $13.96
($11.38)
$ 21.6290%New holding, 142352 sh.142,352
CBMJoel Greenblatt 2012-09-30 Sold Out -0.02%$9.01 - $13.01
($11.05)
$ 21.6296%Sold Out0
CBMJoel Greenblatt 2012-06-30 Buy 0.02%$5.96 - $9.16
($7.07)
$ 21.62206%New holding, 30208 sh.30,208
CBMRobert Olstein 2005-12-31 Sold Out $17.18 - $19.12
($18.4)
$ 21.6218%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBM is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CBM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Haskel William M.Senior Vice President 2014-11-13Sell7,500$24-9.92view
Haskel William M.Senior Vice President 2014-11-06Sell15,000$23.31-7.25view
Cavanagh ShawnEVP & COO 2014-09-11Sell56,251$22.56-4.17view
KLOSK STEVEN MPresident & CEO 2014-09-03Sell126,257$22.01-1.77view
Haskel William M.Senior Vice President 2014-09-02Sell9,400$21.94-1.46view
KLOSK STEVEN MPresident & CEO 2014-08-19Sell4,702$22-1.73view
KLOSK STEVEN MPresident & CEO 2014-08-07Sell1,200$22.52-4view
Haskel William M.Senior Vice President 2014-08-07Sell28,100$22.5-3.91view
WINSCHEL JAMES F JRDirector 2014-08-05Buy600$22.28-2.96view
WINSCHEL JAMES F JRDirector 2014-08-05Sell600$22.28-2.96view

Press Releases about CBM :

    Quarterly/Annual Reports about CBM:

    News about CBM:

    Articles On GuruFocus.com
    Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
    Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
    Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
    Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

    More From Other Websites
    Cambrex To Present At Oppenheimer 25th Annual Healthcare Conference Dec 04 2014
    Cambrex To Present At Oppenheimer 25th Annual Healthcare Conference Dec 04 2014
    Can the Rally in Cambrex (CBM) Shares Continue? Nov 07 2014
    CAMBREX CORP Financials Nov 06 2014
    10-Q for Cambrex Corp. Nov 01 2014
    Cambrex posts 3Q profit Oct 30 2014
    Cambrex posts 3Q profit Oct 30 2014
    Cambrex Corp Earnings Call scheduled for 8:30 am ET today Oct 30 2014
    CAMBREX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 30 2014
    Q3 2014 Cambrex Corp Earnings Release - Before Market Open Oct 30 2014
    Cambrex Reports Third Quarter 2014 Financial Results Oct 30 2014
    Cambrex to Announce Third Quarter 2014 Financial Results on October 30, 2014 Oct 28 2014
    Cambrex to Announce Third Quarter 2014 Financial Results on October 30, 2014 Oct 28 2014
    Halozyme's PEGPH20 Receives FDA Orphan Drug Designation Oct 07 2014
    Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% Oct 06 2014
    Weakness Seen in Vital Therapies (VTL): Stock Falls 6.3% Oct 06 2014
    CorMedix Files IND Application for Neutrolin in the US Sep 30 2014
    Ambit Biosciences (AMBI) Soars: Stock Adds 87.1% Sep 30 2014
    Alimera/pSivida's Iluvien Receives FDA Approval for DME Sep 29 2014
    Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% Sep 29 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK